Human medicines European public assessment report (EPAR): Forxiga, dapagliflozin, Date of authorisation: 11/11/2012, Revision: 34, Status: Authorised

Shortage prevention plan (SPP) workshop, Online, from 22 June 2026, 10:30 (CEST) to 22 June 2026, 12:30 (CEST)

Change management activities delivery plan - HMA-EMA joint Big Data Steering Group

Managing product data quality in PMS: processes, known issues, current status and best practices, Online, from 21 July 2026, 14:00 (CEST) to 21 July 2026, 15:30 (CEST)

EMA/PE/0000273488

Human medicines European public assessment report (EPAR): Byannli (previously Paliperidone Janssen-Cilag International), paliperidone, Date of authorisation: 18/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Oczyesa, octreotide, Date of authorisation: 30/06/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 17, Status: Authorised